MedElevator
Войти в исследования Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cacciapaglia Fabio, De Angelis Rossella, Ferri Clodoveo, Bajocchi Gianluigi, Bellando-Randone Silvia, Bruni Cosimo, Orlandi Martina, Fornaro Marco, Cipolletta Edoardo, Zanframundo Giovanni, Foti Roberta, Cuomo Giovanna, Ariani Alarico, Rosato Edoardo, Lepri Gemma, Girelli Francesco, Zanatta Elisabetta, Bosello Silvia L, Cavazzana Ilaria, Ingegnoli Francesca, De Santis Maria, Murdaca Giuseppe, Abignano Giuseppina, Giorgio Pettiti, Della Rossa Alessandra, Caminiti Maurizio, Iuliano Annamaria, Ciano Giovanni, Beretta Lorenzo, Bagnato Gianluca, Lubrano Ennio, De Andres Ilenia, Giollo Alessandro, Saracco Marta, Agnes Cecilia, Campochiaro Corrado, Lumetti Federica, Spinella Amelia, Magnani Luca, De Luca Giacomo, Codullo Veronica, Visalli Elisa, Iandoli Carlo, Gigante Antonietta, Pellegrino Greta, Cozzi Franco, Lazzaroni Maria G, Generali Elena, Mennillo Gianna, Barsotti Simone, Pagano-Mariano Giuseppa, Furini Federica, Vultaggio Licia, Parisi Simone, Peroni Clara Lisa, Bianchi Gerolamo, Fusaro Enrico, Sebastiani Gian D, Govoni Marcello, D'Angelo Salvatore, Pigatto Erika, Franceschini Franco, Guiducci Serena, Dagna Lorenzo, Doria Andrea, Giuggioli Dilia, Riccieri Valeria, Salvarani Carlo, Matucci-Cerinic Marco, Iannone Florenzo, Systemic Sclerosis Progression Investigation Group of the Italian Society for Rheumatology (SPRING-SIR)
Аннотация
METHODS: Patients with SSc from the SPRING registry, meeting 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria with data on PAH onset, DU status, BOS exposure, and at least 1 year of follow-up between 2015 and 2020, and having no known PAH at baseline, were included. PAH was diagnosed with right heart catheterization during the follow-up, and its incidence rate (IR) was calculated. Kaplan-Meier curves were determined, and multivariate regression identified PAH risk factors.
RESULTS: Among 727 eligible patients with SSc, followed for a median of 2.0 years, 54 (7.4%) developed PAH (IR 3.71 per 100 patient-years [PYs]). Patients with DU who were never exposed to BOS had a higher incidence of PAH (IR 4.90 per 100 PYs) compared to those exposed to BOS, whose rates matched those without DU and who were never exposed to BOS. Risk factors independently associated with PAH development included DU (hazard ratio [HR] 1.86), age (HR 1.05), modified Rodnan skin score > 4 (HR 2.07), interstitial lung disease (HR 2.29), and acetylsalicylic acid treatment (HR 1.78).
CONCLUSION: In our cohort, the presence of DU was confirmed as a leading risk factor for PAH development, and BOS use for DU prevention may reduce this risk. Only patients with DU who were not using BOS had an increased PAH incidence.